2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults
This guideline cites 8 of the 199 landmark trials in our Cardiology register.
- Issued by
- ACC/
AHA - Year
- 2025
- Source
- Jones DW, Ferdinand KC, et al. Hypertension. 2025;82(10):e212–e316.doi 10.1161/HYP.0000000000000249
The 2025 guideline replaces the 2017 document and keeps the defining American position: hypertension begins at 130/80 mmHg (stage 1), where the ESC 2024 guideline still reserves the diagnosis for ≥140/90 mmHg and calls 120–139/70–89 mmHg 'elevated blood pressure'. The two bodies have nevertheless converged on treatment: ACC/AHA target <130/80 mmHg for essentially everyone and encourage <120/80 mmHg where tolerated, against the ESC's on-treatment systolic band of 120–129 mmHg. Drug therapy is now triggered at ≥130/80 mmHg in established cardiovascular disease, diabetes, chronic kidney disease or a PREVENT 10-year risk ≥7.5%, and stage 2 hypertension starts on two agents in a single pill. The guideline also covers hypertensive disorders of pregnancy in far more depth than its European counterpart. The register's trials are grouped by question below.
Blood-pressure targets & intensive lowering2
- 2025BPROADCardiology · HTN · BP targetIn 12,821 patients with type 2 diabetes, intensive blood-pressure control to below 120 mm Hg reduced major cardiovascular events compared with a target below 140 mm Hg.HR 0.79Read →
- 2015SPRINT CoreCardiology · HTN · BP targetIn 9,361 high-risk non-diabetic hypertensive adults, intensive BP control to SBP < 120 mm Hg reduced CV events and all-cause mortality compared with standard control to SBP < 140 mm Hg.HR 0.75Read →
Drug therapy, combinations & resistant hypertension2
- 2015PATHWAY-2Cardiology · HTN · MRAIn 335 patients with drug-resistant hypertension, add-on spironolactone lowered home systolic blood pressure more than placebo, bisoprolol, or doxazosin.Read →
- 2002ALLHATCardiology · HTN · Drug classIn 33,357 hypertensive patients ≥ 55 with ≥ 1 CV risk factor, chlorthalidone was at least as effective as amlodipine or lisinopril for preventing fatal CHD or non-fatal MI.Read →
Renal denervation (device therapy)1
- 2023SPYRAL HTN-ON MEDCardiology · HTN · Renal denervationIn 337 patients with uncontrolled hypertension on 1-3 antihypertensive drugs, radiofrequency renal denervation did not significantly lower 24-hour ambulatory systolic blood pressure at 6 months versus a sham procedure (-1.9 mmHg, 95% CI -4.4 to 0.5).Read →
Hypertension in pregnancy2
- 2022CHAP CoreCardiology · HTN · Hypertension in pregnancyIn 2,408 pregnant women with mild chronic hypertension, antihypertensive treatment targeting a blood pressure below 140/90 mmHg reduced severe pre-eclampsia, medically indicated preterm birth, placental abruption or fetal or neonatal death compared with treatment withheld unless blood pressure reached 160/105 mmHg.RR 0.8295% CI 0.74-0.92Read →
- 2015CHIPSCardiology · HTN · Hypertension in pregnancyIn 987 pregnant women with non-proteinuric pre-existing or gestational hypertension, less-tight blood-pressure control did not reduce pregnancy loss or high-level neonatal care compared with tight control targeting a diastolic pressure of 85 mmHg, but led to far more severe maternal hypertension.OR 1.0295% CI 0.77-1.35Read →
Cardiovascular risk reduction1
- 2000HOPECardiology · Coronary · ACE inhibitorIn 9,297 high-risk patients with vascular disease or diabetes and preserved LV function, ramipril reduced MI, stroke, or cardiovascular death compared with placebo.RR 0.7895% CI 0.70-0.86Read →
Cited landmark trials not yet in the register5
Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.
- 2019SPRINT MIND
Intensive blood-pressure lowering and the risk of mild cognitive impairment and dementia.
- 2010ACCORD BP
Systolic target below 120 mmHg in type 2 diabetes — neutral for the primary endpoint.
- 2021STEP
Intensive blood-pressure lowering in older Chinese adults (not the register trial STEP 1, which is a semaglutide study).
- 2024ESPRIT
Systolic target below 120 mmHg in a broad Chinese cohort — supports the push towards <120 mmHg.
- 2023RADIANCE-HTN / RADIANCE II
Ultrasound renal denervation — the second device platform alongside the register's SPYRAL programme.
Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.